Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures
The objective of this study was to determine the pharmacodynamic (PD) activity of moxifloxacin against four selected Bacteroides fragilis strains (three strains with low MICs and one strain with a high MIC) and two Escherichia coli strains (one strain with a low MIC and one strain with a high MIC) in a pharmacokinetic (PK) in vitro model in pure cultures as well as in mixed cultures. PK/PD assays of moxifloxacin were carried out with an initial maximum concentration of 4.0 mg l−1 and a half-life of 13 h. The E. coli strain with the low MIC was rapidly killed in both pure and mixed cultures in the in vitro PK/PD model, while the E. coli strain with the high MIC was not killed. None of the B. fragilis strains were rapidly killed in pure or mixed cultures. The bacterial numbers of the B. fragilis strains with low MICs were reduced by about one to two logs after 12 h in pure cultures. The presence of an E. coli strain with a low or a high MIC in the mixed culture reduced this effect even further.
BauernfeindA.1997; Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 40:639–651[CrossRef]
BlondeauJ. M.,
LaskowskiR.,
BjarnasonJ.,
StewartC.2000; Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 14:45–50[CrossRef]
EdlundC.,
SabouriS.,
NordC. E.1998; Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 17:193–195[CrossRef]
GolanY.,
McDermottL. A.,
JacobusN. V. & 11 other authors; 2003; Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52:208–213[CrossRef]
GoldsteinE. J. C.,
CitronD. M.,
HudspethM.,
Hunt GerardoS.,
MerriamV.1997; In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother 41:1552–1557
HedbergM.,
NordC. E. on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria; 2003; Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 9:475–488[CrossRef]
KleinkaufN.,
AckermannG.,
SchaumannR.,
RodloffA. C.2001; Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 45:1896–1899[CrossRef]
NaberK. G.,
AdamD. unter Mitwirkung einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e V. (1998). Einteilung der Fluorchinolone. Chemotherapie J 7:66–68
SchaumannR.,
BlatzR.,
BeerJ.,
AckermannG.,
RodloffA. C.2004; Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli
. J Antimicrob Chemother 53:318–324[CrossRef]
SnydmanD. R.,
JacobusN. V.,
McDermottL. A. & 10 other authors; 2002; In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob Agents Chemother 46:3276–3279[CrossRef]
StearneL. E. T.,
KooiC.,
GoessensW. H. F.,
Bakker-WoudenbergI. A. J. M.,
GyssensI. C.2001; In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob Agents Chemother 45:243–251[CrossRef]
StearneL. E. T.,
BuijkS. L.,
MoutonJ. W.,
GyssensI. C.2002; Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. Antimicrob Agents Chemother 46:3712–3718[CrossRef]
SteinG. E.,
SchooleyS.,
KaatzG. W.2003a; Serum bactericidal activity of the methoxyfluoroquinolones gatifloxacin and moxifloxacin against clinical isolates of Staphylococcus species: are the susceptibility breakpoints too high?. Clin Infect Dis 37:1392–1395[CrossRef]
SteinG. E.,
SchooleyS.,
TyrrellK. L.,
CitronD. M.,
GoldsteinE. J. C.2003b; Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 47:1308–1312[CrossRef]
Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures